Vertex Pharmaceuticals
VRTX
$455.34
Share price
2.77%
Change (1 day)
40.70%
Change (1 year)
Categories
P/S ratio for Vertex Pharmaceuticals (VRTX)
P/S ratio as of June 2024 (TTM): 11.2
According to Vertex Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.2254. At the end of 2023 the company had a P/S ratio of 10.6.
P/S ratio history for Vertex Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 10.6 | 27.99% |
| 2022 | 8.30 | 12.49% |
| 2021 | 7.38 | -25.49% |
| 2020 | 9.90 | -27.3% |
| 2019 | 13.6 | -1.82% |
| 2018 | 13.9 | -8.89% |
| 2017 | 15.2 | 41.87% |
| 2016 | 10.7 | -64.24% |
| 2015 | 30.0 | -39.33% |
| 2014 | 49.5 | 245.26% |
| 2013 | 14.3 | 140.39% |
| 2012 | 5.96 | 21.42% |
| 2011 | 4.91 | -90.13% |
| 2010 | 49.7 | -40.87% |
| 2009 | 84.1 | 243.25% |
| 2008 | 24.5 | 57.95% |
| 2007 | 15.5 | -28.9% |
| 2006 | 21.8 | 17.27% |
| 2005 | 18.6 | 123.8% |
| 2004 | 8.31 | -31.45% |
| 2003 | 12.1 | 61.36% |
| 2002 | 7.51 | -46.1% |
| 2001 | 13.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.90 | -65.26% | 🇺🇸 USA |
 AbbVie ABBV | 5.07 | -54.80% | 🇺🇸 USA |
 Gilead Sciences GILD | 2.91 | -74.09% | 🇺🇸 USA |
 Merck MRK | 5.19 | -53.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.79 | -84.04% | 🇺🇸 USA |
 Enanta Pharmaceuticals
ENTA | 3.49 | -68.93% | 🇺🇸 USA |